[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergies":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,95,125,152,184,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100575400","phase-3-evaluation-of-the-efficacy-of-oral-immunotherapy-with-raw-apple-in-patients-allergic-to-birch-pollen-and-apple-prospective-multicenter-comparative-phase-iii-study-100575400",false,"NCT06771791","Evaluation of the Efficacy of Oral Immunotherapy With Raw Apple in Patients Allergic to Birch Pollen and Apple: Prospective, Multicenter, Comparative Phase III Study","ELIO","Inclusion Criteria:\n\n* Patient with allergic rhinitis to birch pollen.\n* Patient with an oral syndrome within 15 minutes of consuming at least one of the first 3 doses of raw apple in the V0 or V1 raw apple oral challenge test.\n* Evidence of sensitization to PR10 proteins in birch pollen and apple: positive prick tests to birch pollen and raw Golden apple and\u002For positive Bet v 1 and Mal d 1 specific IgE assays.\n* Subject affiliated to a social health insurance scheme\n* Subject able to understand the aims and risks of the research and to give dated and signed informed consent\n* For women of childbearing age: negative urine pregnancy test at inclusion visit\n\nExclusion Criteria:\n\n* Severe or uncontrolled asthma\n* Severe obstructive syndrome\n* Active neoplastic disease\n* Active autoimmune disease\n* Eosinophilic esophagitis or other active eosinophilic gastrointestinal pathologies\n* History of bariatric surgery\n* History of anaphylaxis to apples\n* Allergy to cooked apples\n* Contraindication to anti-histamines, corticoids, salbutamol, adrenaline\n* Other contraindication to an oral challenge test\n* Allergy to placebo ingredients\n* Presence of oral syndrome during consumption of placebo in the first oral challenge test\n* Allergenic immunotherapy to birch pollen in progress or completed less than 5 years ago\n* Current treatment with anti-IgE, anti-IL4\u002F13, anti-IL5 or anti-TSLP biotherapy.\n* Impossibility of giving the subject informed information\n* Subject under court protection\n* Subject under guardianship or curatorship\n* Pregnancy","ALL","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Apple-birch pollen-food allergy syndrome is particularly common in Northern and Central Europe (70% of patients allergic to birch pollen), and classically induces an oral syndrome that impairs patients' quality of life. Current treatment is based on food avoidance. However, evidence of the efficacy of this treatment is limited (small numbers, lack of validation with a control group, absence of double-blind evaluation of the primary endpoint in a challenge test against placebo). The aim of oral immunotherapy with raw apple is to improve the management of allergic patients by enabling them to acquire tolerance to raw apple and other rosacea.",[26],"Allergies",[28,29],"allergy","oral immunotherapy","RECRUITING","2026-05-20",{"date":33,"type":34},"2026-05-26","ACTUAL",{"date":36,"type":34},"2025-01-08",{"date":38,"type":20},"2027-05-05",{"name":40,"class":41},"University Hospital, Strasbourg, France","OTHER",4,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":75,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100636706","improved-child-nutrition-and-development-through-social-transfers-100636706","NCT07569172","Improved Child Nutrition and Development Through Social Transfers","Taabo Enhanced Nutrition and Development Through Economic Rewards","TENDER","Inclusion Criteria:\n\n1. Are enrolled in the Taabo multigenerational birth cohort (MGC)\n2. Completed the postpartum interview of the Taabo MGC\n3. Have a child who is within two weeks of their 12-month birthday,\n4. are breastfeeding at time of recruitment,\n5. live in the Taabo HDSS, Côte d'Ivoire\n6. have no illnesses that contraindicates breastfeeding,\n7. had a healthy singleton infant with a birth weight of at least 2500 grams, and\n8. agree to participate and sign an informed consent; if underage (12-17 years), a legal representative will also have to agree to sign the informed consent\n\nExclusion Criteria:\n\n1. Plans to move permanently outside study area\n2. Has a medical, intellectual or psychological disability\n3. Contraindication for breastfeeding\n4. Children born with \\\u003C 2500 grams","FEMALE","12 Years",{"count":54,"type":20},1040,[56],"NA","The goal of this clinical trial is to learn if a conditional social transfer works to improve rates of complementary breastfeeding. It will also learn about the impacts of social transfers on maternal and child health and development. The main questions it aims to answer are:\n\n* Does the social transfer increase complementary breastfeeding rates at 24-months postpartum?\n* Does the social transfer increase complementary breastfeeding duration?\n* Does the social transfer impact child health and development?\n* Does the social transfer impact maternal physical and mental health?\n\nResearchers will compare a conditional social transfer to a control group that only receives education about breastfeeding recommendations to see if a conditional social transfers works to increase complementary breastfeeding.\n\nParticipants will:\n\nReceive a pamphlet explaining the current recommendations of breastfeeding Receive instructions that if they meet the recommendation to breastfeed until 24-months postpartum they receive a social transfer or receive no additional information Complete home visits at 12- and 24-months postpartum Complete detailed questionnaire",[59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,26,74],"Breastfeeding","Breastfeeding Education","Breastfeeding Duration","Breastfeeding Continuation","Child Growth","Stress","Infectious Diseases","Anemia","Child Development","Weight Loss","Blood Pressure","Mental Health","Diarrhea","Coughing","Eczema","Antibiotic Use",[76,77,78,79,80,81,82,83],"breastfeeding","cash transfer","child health","maternal health","mental health","child growth","child development","education","NOT_YET_RECRUITING","2026-04-28",{"date":87,"type":34},"2026-05-06",{"date":89,"type":20},"2026-06-01",{"date":91,"type":20},"2028-02-28",{"name":93,"class":41},"Swiss Tropical & Public Health Institute",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100597484","phase-2-clinical-trial-of-omalizumab-for-allergen-sensitized-and-exposed-individuals-with-copd-100597484","NCT07059091","Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD","Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (COPD-OMA)","COPD-OMA","Inclusion Criteria:\n\n* Able and willing to provide informed consent.\n* Age \\>40 years at screening.\n* Combustible tobacco cigarette exposure \\>10 pack-years.\n* Self-report of physician diagnosis of COPD and currently on dual or triple long-acting inhaled therapy (ICS\u002FLABA\u002FLAMA, ICS\u002FLABA, LABA\u002FLAMA).\n* COPD Assessment Test (CAT) score of \\>15 OR history of at least one documented moderate (requiring treatment with oral corticosteroids) or severe (requiring ED visit or hospitalization) COPD exacerbation in the past year.\n* Participants of childbearing potential must have negative pregnancy test upon study entry.\n* Female (and male) participants with reproductive potential must agree to use FDA approved methods of contraception for duration of study.\n* Post-bronchodilator FEV1\u002FFVC ratio \\\u003C 0.7 and FEV1% predicted \\\u003C 80%.\n* Sensitization to one or more of five common indoor allergens including cat, dog, mouse, cockroach, dust mite defined with positive skin prick test (SPT) (SPT wheal size at least 3 mm greater than negative control). Positive specific IgE testing within 12 months of randomization to cat, dog, mouse, cockroach, or dust mite will be accepted in lieu of skin prick test if SPT is not interpretable or SPT cannot be safely performed.\n* Exposure to the same allergen to which individual is sensitized based on measurement in home settled dust (1 U\u002Fg cockroach, 1 μg\u002Fg mouse, 2 μg\u002Fg dust mite, (Der f 1), 8 μg\u002Fg for cat and dog).\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant to give written informed consent or comply with study protocol.\n* Live in a location other than home (i.e., care facility)\n* Actively breastfeeding.\n* Current asthma diagnosis.\n* Other lung disease (cystic fibrosis, pneumoconiosis, bronchiectasis or otherwise) that is considered the primary respiratory diagnosis and would interfere with participation in the study\n* Reduced life expectancy due to other disease that in the opinion of the investigator may interfere with participation in the study.\n* Participants with severe medical condition(s) that in the view of the investigator prohibits participation in the study.\n* Received or listed for a lung transplant.\n* Surgical or bronchoscopic lung volume reduction surgery in the 12 months prior to screening.\n* History of infection or active infection due to Mycobacterium tuberculosis\n* Active parasitic infection diagnosed and\u002For treated within 6 months of randomization\n* Currently receiving allergen immunotherapy.\n* History of anaphylaxis from medications, foods or otherwise.\n* Current active prescription for epinephrine autoinjector for treatment of severe chronic urticaria.\n* Known sensitivity to study drug(s) or another biologic medication.\n* Use of any other investigational agent for COPD in the last 90 days. If the other investigational agent being used is a biologic agent, this must be washed out for 6 months prior to randomization.\n* Active use of biologic medication (monoclonal antibody) for treatment of respiratory disease in the past 6 months (benralizumab, omalizumab, mepolizumab, resilizumab, dupliumab, tezepelumab, or other similar medication or use of biologic medication for treatment of any non-respiratory disease in the past 3 months.\n* Use of chronic systemic corticosteroids at doses above 10mg daily prednisone or the equivalent.\n* Use of systemic corticosteroid course for acute exacerbation of COPD within 4 weeks of randomization.\n* Weight \\\u003C 66 or \\>330 lbs; and total IgE \\\u003C 30 IU\u002FmL or \\>700 IU\u002FmL; or no available dosing recommendation based on weight and total IgE level.\n* No ICS in background regimen for individuals with blood eosinophil count of \\>300 and systemic steroid requiring exacerbation in the past year, except in case of contraindication to ICS such as thrush, osteoporosis, or pneumonia in the past year.","40 Years",{"count":105,"type":20},334,[107],"PHASE2","This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies.\n\nEach participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.",[110,26],"Chronic Obstructive Pulmonary Disease (COPD)",[112,113,114],"lung disease","COPD","allergies","2026-02-13",{"date":117,"type":34},"2026-02-17",{"date":119,"type":34},"2026-02-12",{"date":121,"type":20},"2031-05",{"name":123,"class":41},"Johns Hopkins University",23,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":94},"100583561","elemental-028-extra-case-studies-100583561","NCT06877923","Elemental 028 Extra Case Studies","Evaluating the Tolerance, Compliance and Acceptability of a Nutritionally Complete Amino Acid-based Nutritional Supplement for the Dietary Management of Conditions With a Severe Impairment of the Gastrointestinal Tract in Children and Adults: a Case Study Series","E028E","Inclusion Criteria:\n\n* Male or female\n* Over 3 years of age\n* Requiring an elemental feed (at least 30% of total energy requirements)\n* Written or electronic informed consent from patient, and\u002For from parent\u002Fcaregiver if applicable\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Requiring parenteral nutrition\n* Major hepatic or renal dysfunction\n* Participation in other studies within 1 month prior to entry of this study\n* Investigator concern around willingness\u002Fability of patient or parent\u002Fcaregiver to comply with protocol requirements","3 Years",{"count":135,"type":20},30,[56],"Elemental 028 Extra is a nutritionally complete ACBS approved amino acid-based (elemental) feed designed to provide adequate daily amounts of both macronutrients and micronutrients when used as a sole source of nutrition and to support patients with severe impairment of the gastrointestinal tract who may require an elemental diet. An upgraded formulation of Elemental 028 Extra with an increased energy, protein content micronutrient profile has been developed to better meet the nutritional requirements of patients.\n\nThis series of case-studies aims to evaluate the acceptability, compliance, and gastrointestinal tolerance of the upgraded formulation of Elemental 028 Extra, in 30 adult and paediatric patients (15 powder and 15 liquid), with conditions where there is a severe impairment of the gastrointestinal tract, such as inflammatory bowel disease, short bowel syndrome, intractable malabsorption, allergic disease, and neurodegenerative diseases, and an elemental feed is required. The case study will last 29 days in total, including a 1-day baseline period followed by a 28-day intervention period. The case studies will be conducted across multiple centres in the UK, to meet the UK ACBS and GMS requirements for acceptability studies.",[139,140,141,142,26,143],"Gastrointestinal Disease","Inflammatory Bowel Disease (IBD)","Short Bowel","Malabsorption","Neurodegenerative Disorders",{"date":117,"type":34},{"date":146,"type":34},"2025-05-01",{"date":148,"type":20},"2027-02",{"name":150,"class":151},"Nutricia UK Ltd","INDUSTRY",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":51,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100448470","effects-of-the-mediterranean-diet-during-pregnancy-on-the-onset-of-allergies-in-the-offspring-100448470","NCT05119868","Effects of the Mediterranean Diet During Pregnancy on the Onset of Allergies in the Offspring","Effects of the Mediterranean Diet During Pregnancy on the Onset of Allergies in the Offspring: a Multi-center Randomised-controlled Trial (the PREMEDI Project)","PREMEDI","Inclusion Criteria:\n\n\\- healthy women (aged 20-35 years), at first trimester of pregnancy, of at risk for atopy baby\n\nExclusion Criteria:\n\n* concomitant presence of infections;\n* concomitant presence of malignancies;\n* concomitant presence of major gastrointestinal malformations;\n* concomitant presence of immunodeficiencies;\n* concomitant presence of autoimmune diseases;\n* concomitant presence of chronic inflammatory bowel diseases;\n* concomitant presence of functional gastrointestinal disorders;\n* concomitant presence of celiac disease;\n* history of abdominal surgery with gastrointestinal resection;\n* concomitant presence of neuropsychiatric disorders;\n* concomitant presence of central nervous system disorders;\n* vegan diet;\n* twin pregnancy;\n* concomitant presence of genetic disorders;\n* concomitant presence of metabolic disorders.",true,"20 Years","35 Years",{"count":164,"type":20},276,[56],"Allergy prevalence is increasing steadily with some describing as the \"epidemic of the twenty-first century\". Maternal diet during pregnancy has been linked to offspring allergy risk, so it represents a potential target for allergy prevention. The Mediterranean Diet (MD) is considered one of the healthiest dietary models which exerts regulatory effects on immune system, due to the synergistic and interactive combinations of nutrients. We aim to study the effects of MD in pregnancy on the onset of allergic diseases at 2 years of age in the offspring.",[26,168,169,170,171,172,173,174],"Obesity","Gestational Complications","Gestational Weight Gain","Perinatal Condition","Birth Weight","Chronic Diseases in Children","Breast Feeding","2026-02-11",{"date":119,"type":34},{"date":178,"type":34},"2021-11-02",{"date":180,"type":20},"2026-03-10",{"name":182,"class":41},"Federico II University",2,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100588602","phase-2-omalizumab-weight-based-dosing-efficacy-trial-100588602","NCT06943534","Omalizumab Weight-Based Dosing Efficacy Trial","OWED-T","Inclusion Criteria:\n\n* A positive prick skin test (PST) with a wheal ≥ 6 mm to at least two of the relevant foods (peanut, cashew, walnut, egg, or milk)\n* Positive food specific IgE (≥2.0 kUA\u002FL) to at least two of the relevant foods\n* A positive history of clinical reaction to at least one of the qualifying foods other than the challenge-qualifying food\n\n(If meeting above criteria):\n\n* Positive oral food challenge (OFC) to one of the potentially qualifying foods at a cumulative dose of ≤144 mg (maximum tolerated dose ≤30 mg)\n\nExclusion Criteria:\n\n* Weight \\>80 kg at time of screening\n* Clinically significant laboratory abnormalities at screening.\n* Sensitivity or suspected\u002Fknown allergy to any ingredients (including excipients) of omalizumab.\n* Poorly controlled or severe asthma\u002Fwheezing at screening\n* History of severe anaphylaxis to participant-specific foods that will be used in this study, defined as neurological compromise, PICU admission f for continuous epinephrine for hypotension or severe respiratory compromise requiring intubation.\n* Treatment with a burst of oral, intramuscular (IM), or intravenous (IV) steroids of more than two days for an indication other than asthma\u002Fwheezing within 30 days of screening.\n* Currently receiving oral, IM, or IV corticosteroids, tricyclic antidepressants, or β-blockers.\n* Past or current history of eosinophilic gastrointestinal disease within three years of screening.\n* Past or current history of cancer, or currently being investigated for possible cancer.\n* Past or current history of any food immunotherapy (e.g., OIT, SLIT, EPIT) within 6 months of screening.\n* Treatment with monoclonal antibody therapy, or other immunomodulatory therapy within 6 months of screening.\n* Inability to discontinue antihistamines for minimum wash-out periods required for SPTs or OFCs.\n* Pregnant or breastfeeding or intending to become pregnant during the study.\n* Evidence of clinically significant chronic disease.","1 Year","55 Years",{"count":135,"type":20},[107],"This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.",[26,197],"Food Allergy",[199],"omalizumab","2026-02-03",{"date":202,"type":34},"2026-02-05",{"date":204,"type":34},"2025-07-03",{"date":206,"type":20},"2028-04-01",{"name":208,"class":41},"Massachusetts General Hospital",3,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":160,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":218,"phases":4,"briefSummary":219,"conditions":220,"keywords":234,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100609070","healthspan-connect-programme-of-research-100609070","NCT07209774","Healthspan Connect Programme of Research","Inclusion Criteria:\n\n* Age 12 years or older at time of enrollment.\n* Resident in the United Kingdom.\n* Able to participate in the study using digital tools (smartphone, tablet, or computer).\n* Able to provide informed consent (digital consent accepted).\n* For participants aged 12-15 years: must have parent\u002Fguardian consent in addition to their own assent.\n\nExclusion Criteria:\n\n* Individuals unable to provide informed consent (or parental consent where applicable).\n* Individuals not resident in the UK.\n* Individuals unable to complete study requirements due to lack of internet access, inability to use digital devices, or severe digital literacy barriers.",{"count":217,"type":20},100000,"OBSERVATIONAL","Healthspan Connect is a new research programme designed to understand what helps people stay healthy as they age. The programme will explore how lifestyle, environment, genetics, and social factors influence healthy ageing and overall wellbeing.\n\nThe programme will recruit participants aged 12 years and older across the UK. By including adolescents, the programme aims to understand how early life behaviours and experiences shape long-term health. There is no upper age limit, and people from all backgrounds are encouraged to participate. Special pathways ensure that young participants provide consent in an age-appropriate way.\n\nHealthspan Connect is a digital and home-based study, meaning participants can take part from home using smartphones, computers, and online surveys. Participants may also be asked to collect samples such as blood, saliva, stool, urine, or other biological specimens at home using easy-to-use kits. In some sub-studies, participants may be invited to attend research visits for additional tests, scans, or clinical assessments. Family members and close contacts may also be invited to participate in some studies.\n\nThrough Healthspan Connect, researchers aim to:\n\n* Identify the biological, environmental, and social factors that help people live longer, healthier lives.\n* Understand how different groups, including those historically underrepresented in research, experience ageing.\n* Explore ways to support behaviour changes that improve health over the lifespan.\n* Provide near real-time information to inform health policies and interventions.\n\nParticipants may also be asked for permission to link their information with health records, education records, and environmental data to better understand health outcomes over time.\n\nThis programme will serve as a flexible platform for multiple sub-studies, allowing participants to contribute to a wide range of research questions related to healthy ageing, resilience, and long-term health. All data and biological samples will be stored securely and used to advance scientific knowledge, with participant privacy carefully protected.",[221,70,222,223,224,225,226,227,228,229,230,231,26,232,233],"Cancer","Ageing Well","Resilience","Cognitive Health","Psychological Health","Environmental Health Effects","Cardiovascular Health","Metabolic Health","Neurological Health","Musculoskeletal Health","Respiratory Health","Eye Health","Other",[235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256],"Healthy ageing","Healthspan","Longevity","Ageing resilience","Life course determinants","Multiple long-term conditions","Digital health research","Remote monitoring","Mobile health (mHealth)","Wearables","Biobank","Biological specimen collection","Home-based sample collection","Epidemiology","Longitudinal cohort study","Adolescents and ageing","Underrepresented populations in research","Behaviour change","Environmental exposures","Data linkage","Electronic health records (EHR)","United Kingdom","2025-09-29",{"date":259,"type":34},"2025-10-07",{"date":261,"type":20},"2026-01-05",{"date":263,"type":20},"2056-01-05",{"name":265,"class":41},"King's College London"]